Jasmine Yu is an IPilogue Writer and a 1L JD Candidate at the University of Toronto. After numerous delays over two years, amendments to the Patented Medicines Regulations, which governs Canada’s Patented…
Category: Access to Medicines
How IP Waivers Can Help Manage the Omicron Strain
Shannon Flynn is a Guest Writer and the Managing Editor of ReHack Magazine. Over two years have passed since the SARS-CoV-2 virus, better known today as COVID-19, made its first…
Reducing the Canadian carbon footprint through ESG Energy’s granting of exclusive patent rights
Meena Alnajar is an IPilogue Writer, IP Innovation Clinic Fellow, and a 2L JD Candidate at Osgoode Hall Law School. Leaves may be falling in time for autumn, but…
Insulin Biohackers: Shaking Up a Billion-Dollar Industry
Natalie Bravo is an IPilogue Writer and a 2L JD Candidate at Osgoode Hall Law School. Brief History of Insulin In 1921, Dr. Frederick Banting, Charles Best, and James…
Biden Support for Covid-19 Intellectual Property Waiver: A Step Below Progress?
Ryan Erdman is an IPilogue Writer and a 2L JD Candidate at Osgoode Hall Law School. In a truly monumental achievement in scientific innovation, there are now over a dozen authorized COVID-19…
in Access to Medicines, Blogs, Commercialization, Development, Innovation, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
1911
Broken Promises: Utility Standards and Patent Applications in Canada
The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…